Tscan Therapeutics Inc (NASDAQ: TCRX) kicked off on Friday, down -6.03% from the previous trading day, before settling in for the closing price of $1.16. Over the past 52 weeks, TCRX has traded in a range of $1.02-$6.22.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -14.41%. While this was happening, its average annual earnings per share was recorded -10.90%. With a float of $46.42 million, this company’s outstanding shares have now reached $52.47 million.
Tscan Therapeutics Inc (TCRX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Tscan Therapeutics Inc is 18.20%, while institutional ownership is 60.65%. The most recent insider transaction that took place on May 19 ’25, was worth 1,666,553. In this transaction 10% Owner of this company bought 1,388,794 shares at a rate of $1.20, taking the stock ownership to the 6,746,141 shares. Before that another transaction happened on May 20 ’25, when Company’s 10% Owner bought 1,200,000 for $1.20, making the entire transaction worth $1,440,000. This insider now owns 7,946,141 shares in total.
Tscan Therapeutics Inc (TCRX) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.25 earnings per share (EPS), higher than consensus estimate (set at -0.29) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.36% during the next five years compared to -14.41% drop over the previous five years of trading.
Tscan Therapeutics Inc (NASDAQ: TCRX) Trading Performance Indicators
Take a look at Tscan Therapeutics Inc’s (TCRX) current performance indicators. Last quarter, stock had a quick ratio of 7.06. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.10, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.13 in one year’s time.
Technical Analysis of Tscan Therapeutics Inc (TCRX)
The latest stats from [Tscan Therapeutics Inc, TCRX] show that its last 5-days average volume of 1.81 million was superior to 0.5 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 3.89%.
During the past 100 days, Tscan Therapeutics Inc’s (TCRX) raw stochastic average was set at 1.33%, which indicates a significant decrease from 1.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1730 in the past 14 days, which was higher than the 0.1408 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9071, while its 200-day Moving Average is $1.7523. Now, the first resistance to watch is $1.1433. This is followed by the second major resistance level at $1.1967. The third major resistance level sits at $1.2333. If the price goes on to break the first support level at $1.0533, it is likely to go to the next support level at $1.0167. The third support level lies at $0.9633 if the price breaches the second support level.
Tscan Therapeutics Inc (NASDAQ: TCRX) Key Stats
The company with the Market Capitalisation of 61.86 million has total of 56,748K Shares Outstanding. Its annual sales at the moment are 2,820 K in contrast with the sum of -127,500 K annual income. Company’s last quarter sales were recorded 3,080 K and last quarter income was -36,950 K.
